Boston Scientific Corporation (NYSE: BSX) today announced data supporting use of the company's FARAPULSE™ Pulsed Field Ablation (PFA) Platform and WATCHMAN™ Left Atrial Appendage Closure (LAAC) ...
The second quarter is expected to be the most challenging period of 2026 due to difficult year-over-year comparisons in the EP and WATCHMAN segments. Management anticipates a return to market-level ...
Boston Scientific Corporation (NYSE:BSX) is one of the most oversold healthcare stocks to invest in. Truist cut the price ...
For the current quarter ending in June, Boston Scientific expects its per-share earnings to range from 82 cents to 84 cents. The company expects full-year earnings in the range of $3.34 to $3.41 per ...
Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.203 billion during the first quarter of 2026 ...
Boston Scientific Corp. reports first-quarter earnings Wednesday morning, a pivotal moment for investors trying to determine ...
Shares of Boston Scientific Corp. slipped 5.04% to $60.99 Monday, on what proved to be an all-around dismal trading session for the stock market, with the S&P 500 Index falling 0.24% to 7,109.14 and ...
Boston Scientific Corporation secured net sales of $5.203 billion during the first quarter of 2026, growing 11.6% overall.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Boston Scientific ...
Boston Scientific Corp. BSX shares are in the spotlight on Tuesday after Stifel maintained a Buy rating and lowered its price ...
Boston Scientific (BSX) drops 36% YTD to $60.54 as analysts lower targets ahead of Q1 earnings. Despite cuts, firms maintain ...
Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results